Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient

Abstract

Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause mortality. However, the roles of metformin in cardiac arrhythmias are still unclear. It has been shown that metformin was associated with decreased incidence of atrial fibrillation in diabetic patients with and without myocardial infarction. This could be due to the effects of metformin on preventing the structural and electrical remodeling of left atrium via attenuating intracellular reactive oxygen species, activating 5′ adenosine monophosphate-activated protein kinase, improving calcium homeostasis, attenuating inflammation, increasing connexin-43 gap junction expression, and restoring small conductance calcium-activated potassium channels current. For ventricular arrhythmias, in vivo reports demonstrated that activation of 5′ adenosine monophosphate-activated protein kinase and phosphorylated connexin-43 by metformin played a key role in ischemic ventricular arrhythmias reduction. However, metformin failed to show anti-ventricular arrhythmia benefits in clinical trials. In this review, in vitro and in vivo reports regarding the effects of metformin on both atrial arrhythmias and ventricular arrhythmias are comprehensively summarized and presented. Consistent and controversial findings from clinical trials are also summarized and discussed. Due to limited numbers of reports, further studies are needed to elucidate the mechanisms and effects of metformin on cardiac arrhythmias. Furthermore, randomized controlled trials are needed to clarify effects of metformin on cardiac arrhythmias in human.

Introduction

Metformin initially received approval from the U.S. Food and Drug Administration for type 2 diabetes in 1995 [1]. Since then, an accumulating body of evidence has shown various benefits of metformin beyond the antihyperglycemic effects [2]. In the case of cardiovascular protection, it has been shown that metformin exerted many benefits including a reduction in blood pressure, left ventricular mass [3], stroke [4], heart failure [5, 6], myocardial infarction (MI), cardiovascular death, and all-cause mortality [7–10]. Several mechanisms behind the cardioprotective effects have been proposed. Metformin is known as 5′ adenosine monophosphate-activated protein kinase (AMPK) activator. Metformin activates AMPK through tyrosine-protein kinase c-Src/phosphatidylinositol-3-kinase (PI3K) pathway activation [11], and/or increased AMP:ATP ratios via inhibition of mitochondrial complex 1 [12]. Once activated, AMPK stimulated endothelial nitric oxide synthase, fatty acid oxidation, glucose transport, glycolysis, cellular calcium handling, ATP-sensitive potassium channels (K_ATP), autophagy, and inhibited protein synthesis, cell proliferation, endoplasmic reticulum stress, endothelial lipotoxicity, and NF-kB pathway, which helped conserve/generate ATP, prevent necrosis/apoptosis, decrease oxidative stress, decrease inflammation, and prevent atherosclerosis [11, 13].

During ischemic/reperfusion injury, metformin could reduce myocardial infarct size by preserving energy homeostasis via an increase in myocardial adenosine 5′ monophosphate-activated protein kinase (AMPK) activity [14], and stimulating adenosine receptors via increased intracellular formation of adenosine [15]. Once the A1, A2A, A2B, and A3 adenosine receptors in myocardial cells were stimulated, they coupled to G proteins and triggered a range of mostly beneficial responses. These involved activation of protein kinase C, phosphatidylinositol-3-kinase/survival protein kinases (PI3K/Akt), and mitogen-activated protein kinase (MAPK), which ultimately targeted mitochondrial ATP-sensitive potassium (K_ATP) channels and limited the opening of mitochondrial permeability transition pores (mPTP), leading to protection against necrosis and apoptosis [16–18].

In diabetes-related vasculopathy, metformin was shown to decrease low-density lipoprotein-cholesterol (LDL-C) which may retard the progression of atherosclerosis [19, 20]. However, it has been shown that metformin may not reduce LDL-C, and the anti-atherosclerotic effect of metformin could be independent of lipids-lowering effect [21] and through the improved endothelial function via AMPK [22], downregulation of angiotensin II type 1 receptors, increased antioxidant superoxide dismutase-1 [23], increased cholesterol efflux in macrophages, and decreased plasminogen activator inhibitor type 1 activity, fibrinogen level, C-reactive proteins protein, and NF-kB pathway activation in the vascular wall [24–26]. Heart rate variability, which reflects sympathovagal balance and risk of cardiovascular death in diabetes [27], was also improved following metformin treatment [28].

Despite these cardiovascular benefits of metformin, the roles of metformin on the antiarrhythmic effects are still unclear. In this review, reports regarding the effects and mechanisms of metformin on cardiac arrhythmias are comprehensively summarized and presented. Consistent findings and controversial reports from in vivo and clinical studies are also presented and discussed. This information could provide an important foundation for further work on the benefits of metformin as an antiarrhythmic agent in the future.

Effects of metformin on atrial arrhythmias: evidence from in vitro and in vivo studies

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, and has been known for its progressive nature and for heightening the risk of stroke [29]. AF mainly triggered by the pulmonary veins [30] and is perpetuated by multiple wavelets [31, 32] and rotors [33, 34] in the left atrium (LA). Specific stressors, such as heart failure, diabetes, hypertension, obesity, coronary artery disease, aging, or genetic predisposition, have been shown to cause atrial dilatation, interstitial fibrosis, and shortened atrial effective refractory period (AERP) in the LA [29]. An increased atrial pressure in heart failure led to atrial dilatation and fibrosis, which is the structural substrate for AF [35]. It has been demonstrated that insulin resistance and diabetes induced structural, electrical, electro-mechanical, and autonomic remodeling in atria, which subsequently become arrhythmogenic substrates for AF [36]. An increased transforming growth factor-beta (TGF-β), connective tissue growth factor expression, and diastolic dysfunction also led to atrial dilation and fibrosis [36, 37]. An increased L-type calcium current (I_Ca,L), decreased connexin-43 (Cx43) expression, and reduced sodium current could lead to prolonged action potential duration (APD), increased atrial effective refractory period (AERP) dispersion, and conduction slowing [36, 37]. The combination of conduction delay and atrial fibrosis was shown to lead to excitation-contraction uncoupling [36]. Conversely, AF itself can lead to worsened heart failure due to irregular ventricular filling, loss of atrial contraction, rapid ventricular rates, and tachycardia-induced cardiomyopathy [35]; adverse LA structural remodeling, including myolysis, glycogen deposition, and electrical remodeling, resulting in the promoting of the perpetuation of AF and the setting off of a vicious cycle known as “AF begets AF” phenomenon [38, 39].

AMPK can be activated by metabolic stress and AF, and helps maintain L-type calcium channel current (I_Ca,L), I_Ca,L-triggered Ca²⁺ ion transients amplitude, sarcoplasmic reticulum Ca²⁺ content, and cell contractility [40]. Chronicity of AF affects AMPK expression in dogs and humans, with increased AMPK in paroxysmal AF, while paradoxically decreased AMPK in longstanding persistent AF [40–43]. Nonetheless, metformin has been shown to further increase AMPK expression in both situations [41, 42], along with improving insulin resistance, thus it may help prevent atrial arrhythmogenesis.

After rapid atrial pacing in non-diabetic HL-1 atrial cells, metformin was shown to prevent adverse cellular remodeling by attenuating tachy-induced myolysis and reducing intracellular reactive oxygen species (ROS) [44]. In neonatal rat cardiomyocytes, metformin attenuated rapid pacing-induced shortened field potential duration (FPD) by increasing Cx43 gap junction and zonula occluddens-1 (ZO-1) expression via AMPK activation [42]. Not only the direct effects on atrial cells, metformin could improve calcium homeostasis in HL-1 cells by attenuating inflammation of the co-cultured adipocytes via an increased peroxisome proliferator-activated receptor gamma (PPARγ)/adiponectin (APN) and suppressed tumor necrosis factor-alpha (TNFα) [45].

Metformin concentration used in the cell experiments were mostly supra-pharmacological doses. Maximal metformin approved daily dose of 2.5 g results in plasma level of 0.01–0.04 mmol/L [46], while metformin concentration used in the cell experiments ranged from 0.5 to 4 mmol/L [42, 44, 45]. Although low and high metformin concentration can both activate AMPK, the high concentration (> 0.25 mmol/L) also exerted its effects through non-AMPK dependent pathways [46]. Therefore, one should be cognizant when attempting to imply mechanisms and effects of metformin from in vitro reports to clinical studies.

In non-diabetic dogs, rapid atrial pacing (AF model) increased lipid deposition in the left atrial appendages which was associated with AERP shortening and dispersion [41]. These structural and electrical changes are substrates for AF. Administration of metformin for two weeks prior to rapid atrial pacing improved fatty acid β-oxidation via the AMPK/PPAR-α/very long-chain specific acyl-CoA dehydrogenase (VLCAD) signaling pathway, resulting in decreased lipid deposition in the left atrial appendages, and therefore prevented AERP shortening/dispersion. Another study with rapid atrial pacing in dogs showed similar metformin benefits in attenuating shortened AERP, AERP dispersion, and AF reduction via AMPK/Cx43 pathway [42]. Cx43 is the predominant gap junction protein in the heart. AF caused a reduction in atrial Cx43 protein in pigs [47, 48]. Cx43 gene transfer restored atrial Cx43 protein content, improved atrial conduction, and prevented AF [47, 48]. AMPK activation promoted K_ATP opening and surface expression, leading to inhibition of gap junction permeability, increase Cx43 expression, and subsequently attenuate atrial arrhythmia [49].

Obesity and diabetes were independently associated with increased risk of new-onset AF. This is partly due to an expansion of epicardial adipose tissue (EAT) under these conditions [50]. EAT is in direct contact with atrial tissues. EAT infiltration and adipokines secreted by EAT could cause atrial inflammation, structural and electrical remodeling, and subsequent AF [51]. Chronic metformin for 6 weeks reduced EAT, inhibited reactive oxygen species (ROS)/NF-kB, decreased pro-inflammatory adipokines (IL-6, TNF-α, and TGF-β1), upregulated adiponectin in LA/EAT, reduced atrial fibrosis, and AF [45].

Small conductance calcium-activated potassium (SK) channels affect cardiac action potential duration during the late-phase repolarization [52]. SK channels are activated by calcium, therefore integrate intracellular calcium changes with membrane potential. SK channels express more in atrial than ventricular myocytes [52]. There are three subtypes, SK1 (K_Ca2.1), SK2 (K_Ca2.2), and SK3 (K_Ca2.3), which are encoded by KCNN1, KCNN2, and KCNN3, respectively [52]. Fu et al. reported an association of SK channels and atrial arrhythmias in diabetic rats [53]. They demonstrated that decreased SK2, increased SK3 expression, distorted current-voltage relationship, and overall SK current reduction in diabetic rats led to prolonged APD and subsequent atrial arrhythmias. Chronic metformin treatment for 3 months reduced atrial arrhythmias by normalizing the APD via an increased SK2, decreased SK3, increased overall SK current, and restored normal current-voltage relationship [53]. Specifically, overexpression of SK3 has been shown to be associated with heart block and atrial arrhythmias [53, 54]. Moreover, the role of SK channels in human AF was reported in genome-wide association analysis, demonstrating an association between single-nucleotide polymorphism in KCNN3 gene with lone AF [52].

In conclusion, rapid atrial pacing induced AF via structural (increased ROS, myolysis, lipid deposition, left atrial fibrosis) and electrical (shortened AERP, increased AERP dispersion) remodeling. Metformin was shown to attenuate this adverse remodeling and break in the “AF begets AF” process. Despite limited in vitro and in vivo reports as summarized in Tables 1 and 2, these in vitro and in vivo studies consistently supported the beneficial effects of metformin on atrial arrhythmias via protection against atrial structural and electrophysiological remodeling in both diabetic and non-diabetic settings. Figure 1 summarized mechanisms behind the protective effects of metformin on atrial arrhythmias.

Table 1.

Effects of metformin on atrial arrhythmias: reports from in vitro studies

Model	Metformin (dose/ duration)	Key results and major findings							Interpretation	References
		Energy homeostasis	Oxidative stress	Intra-cellular Ca	Inflammation	Cx43	EP changes	Cell structure
HL-1 atrial cells paced with 4 Hz (240 bpm) for 24 h	1 mmol/L for 2 h	–	↓ROS	–	–	–	–	↑Cytoplasmic myosin heavy chain/nuclear area ratio ↑Troponin I	Metformin provided cardioprotection against AF-related adverse remodeling via attenuating tachy-induced myolysis and oxidative stress of atria cells	[44]
Neonatal rat cardiomyocytes and HL-1 cell with field stimulation at 3 Hz for 12 h	0.5 & 1 mmol/L	↓cAMP→ ↓pSrc→ ↑AMPK→ ↑Cx43	–	–	–	↑	↑FPD	↑ZO-1	Metformin attenuated a shortened FPD possibly by improved gap junction function via AMPK activation, increased ZO-1 and Cx43 expression	[42]
3T3-L1 mature adipocytes with LPS for 24 h then co-cultured with HL-1 atrial cell	4 mmol/L incubated with adipocytes for 12 h	–	–	↓Ca, ↑SERCA2a, ↑pPLN in HL-1 cell	↑PPARγ/ APN, and ↓TNFα in adipocytes	–	–	–	Metformin improved Ca2+ homeostasis in HL-1 cell by attenuated the inflammatory interaction between adipocytes and HL-1 cell via an increased PPARγ/APN and suppressed TNFα	[45]

AMPK 5' adenosine monophosphate-activated protein kinase, APN adiponectin, Ca calcium, cAMP cyclic adenosine monophosphate, Cx43 connexin 43, FPD field potential duration, LPS lipopolysaccharide, PPARγ peroxisome proliferator-activated receptor gamma, pPLN phosphorylated phospholamban, p-Src phopho-Src(Tyr416), ROS reactive oxygen species, SERCA2a sarcoplasmic reticulum Ca²⁺-ATPase2a, TNFα tumor necrosis factor alpha, ZO-1 Zonula occludens-1

Table 2.

Effects of metformin on atrial arrhythmias: reports from in vivo studies

Model	Metformin (dose/ duration)	Key results and major findings								Interpretation	References
		Energy homeostasis	ROS	Ion channel	Inflammation	Cx43	EP changes	Structural remodel	AF
Non-DM dogs with atrial rapid pacing (1200 bpm for 6 h)	100 mg/kg/days for 2 weeks	↑↑AMPK -↑PPARα, PGC-1α, VLCAD, CPT-1	–	–	–	–	↑AERP ↓AERPd	↓FFA/TG /lipid deposition in LAA	–	Metformin improved EP disorders caused by atrial rapid pacing via ↓lipid accumulation and promoted FAO in AF models through AMPK/PPAR-α/VLCAD pathway	[41]
Non-DM dogs with rapid atrial pacing (400 bpm for 6 weeks)	100 mg/kg/days for 1 week prior then 6 weeks	–	↓ in LA/EAT	–	– ↑APN, adipoR1 – ↓ IL-6, NF-kB, TNFα, TGFβ1	–	↑AERP ↓AERPd	↓LA fibrosis and EAT	↓	Metformin reduced AF and atrial fibrosis by inhibited ROS/NF-kB, reduced epicardial fat, pro-inflammatory adipokines, and upregulated adiponectin in LA/EAT	[45]
Non-DM dogs with rapid atrial pacing 400 bpm	100 mg/kg/days for 1 week then pace for 180/ 360 min (acute)	–	–	–	–	↑	↔ AERPd	–	–	Metformin reduced AF by preventing adverse electrical remodeling via increase AMPK and Cx43 expression in chronic AF model. Metformin mildly increased Cx43 in acute pacing and could not attenuate AERPd	[42]
	100 mg/kg/days with pace for 6 weeks (chronic)	↑AMPK ↔ mito-chondrial morphology	–	–	–	↑↑	↑AERP ↓AERPd	↔Irregular myocardial fibers	↓
GK T2DM rats	300 mg/kg/days for 3 months			- ↔ SK1, ↑SK2,↓SK3 -↑SK current -↓distorted current-voltage relationship			↓ APD	↓ Atrial myofilament irregularity and fibrosis	↓	Metformin reduced atrial arrhythmia in DM GK rats via decreased atrial remodeling and normalized APD via restoring SK current	[53]

adipoR1 adiponectin receptor 1, AERP atrial effective refractory period, AERPd AERP dispersion, AMPK 5' adenosine monophosphate-activated protein kinase, APD action potential duration, bpm beats per minutes, APN adiponectin, Ca calcium, CPT-1 Carnitine palmitoyltransferase I, EAT epicardial adipose tissue, EP electrophysiologic, FAO fatty acid oxidation, FFA free fatty acid, GK Goto-Kakizaki, LA left atrium, LAA left atrial appendage, PGC-1α peroxisome proliferator-activated receptor-gamma coactivator 1α, PPAR-α peroxisome proliferator-activated receptor α, ROS reactive oxygen species, SK channels small conductance calcium-activated potassium channels, TG triglyceride, TGFβ1 transforming growth factor beta1, TNFα tumor necrosis factor alpha, VLCAD Very long-chain specific acyl-CoA dehydrogenase

Fig. 1.

Effects of metformin on atrial arrhythmias. Atrial fibrillation, obesity, insulin resistance, and diabetes mellitus can cause atrial structural, electrical, electromechanical, and autonomic adverse remodeling. These remodelings become arrhythmogenic substrates and set out a vicious cycle known as “AF begets AF”. Metformin exerts protective effects through various mechanisms. Red arrow shows adverse effects from atrial fibrillation, obesity, insulin resistance, and diabetes. Green rectangle shows pathway that metformin blocked. Solid green arrow shows protective mechanisms of metformin directly demonstrated from the studies in Tables 1 and 2. Dotted green arrow indicates protective mechanism of metformin from other studies in the text

Effects of metformin on atrial arrhythmias: evidence from clinical trials

Observational studies demonstrated that metformin was associated with a reduction in AF incidence, when compared to other anti-diabetic medications, among patients who had diabetes or presented with acute MI [44, 55, 56]. However, the anti-atrial arrhythmias effects seemingly vanished in patients of older age (> 65 years old) or had more advanced diabetes [44, 55, 57]. One study has shown an association between longer DM duration and more advanced atrial remodeling [58]. Older age is known to be associated with more comorbidities (e.g. coronary artery disease, congestive heart failure, hypertension), more fibrous tissue interspersed between myocytes, and electrophysiologic changes of LA [59, 60]. These factors could contribute to the fewer anti-AF effects of metformin seen in these populations. Due to the limitations as an observational cohort, the dose and duration of metformin used in these studies varied and were not reported in detail, thus limiting the analysis of adequacy of dosage and treatment duration.

AF following cardiac surgery occurs not uncommonly with an incidence ranged from 5–64%, and it is associated with prolonged hospital stay, extra cost of care, greater in-hospital mortality, and worse long-term survival [61]. Several mechanisms have been proposed to be accountable for post cardiac surgery AF, including perioperative inflammation, pericarditis, electrical remodeling, autonomic imbalance, atrial incision, perioperative ischemia, and increased oxidative stress [61, 62]. Since metformin has been shown to exert benefits on reducing oxidative stress and inflammation [23, 26, 44, 63–67], it was expected that it might reduce AF in these circumstances. Unfortunately, a randomized controlled trial of 3-day metformin treatment before surgery did not decrease troponin I level or incidence of post cardiac surgery AF in patients without diabetes as compared to placebo [68]. Consistent with this report, metformin was also not associated with decreased post cardiac surgery AF in a retrospective cohort of matched DM patients [69]. Although no in vitro or in vivo studies had directly looked at the performance of metformin on atrial arrhythmias under post cardiac surgery circumstances, these results may imply an ineffectiveness of metformin in preventing AF in post cardiac surgery in the case of both diabetic and non-diabetic patients. All of these reports are summarized in Table 3.

Table 3.

Effects of metformin on atrial arrhythmias: reports from clinical trials

Model	Type of study/No. of patients/follow-up	Metformin (dose/duration)	AF incidence	Interpretation		References
Taiwanese DM patients treated with metformin alone vs. other meds (mean age 58 years)	Longitudinal cohort/85,198 metformin users and 560,512 non-users/mean follow-up 5.4 years	Various dose and duration of metformin	- ↓ AF incidence in the first 3 years after diagnosis of DM - HR of 0.81, p < 0.0001	Metformin associated with decreased incidence of AF during the first 3 years after the diagnosis of DM		[44]
Taiwanese DM patients w/ or w/o metformin (mean age 69 years)	Nested case control study/2882 AF and 11,528 controls/mean DM duration 3.9 years	- Various dose - At least 6 months of drug used	- ↓ AF incidence - OR 0.81, 95%CI 0.71–0.95	Metformin associated with decreased new onset AF		[55]
Hospitalized DM patients with AMI w/ or w/o metformin (mean age 56)	Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI	Various dose	- Metformin alone: <-> 28-day AF incidence, OR 1.1 (95%CI 0.3–4.0) - Metformin + other anti-DM drugs: ↓28-day AF incidence, OR 0.2 (95% CI 0.1–0.7)	Metformin in combination with other anti-DM drugs associated with decreased AF incidence 28-day post AMI		[56]
≥ 65 years old Taiwanese DM patients w/ or w/o metformin (mean age 73 years)	Nested case-control/1958 cases and 7832 controls/mean DM duration 8 years	- Various dose - At least 12 months of drug used	- <-> AF incidence - OR 1.01 (0.88–1.15)	Metformin was not associated with decreased AF incidence in elderly DM population		[57]
Patients without DM undergoing cardiac surgery randomized to metformin or placebo (mean age 65 years)	Double-blind, randomized controlled trial/57 to metformin, 57 to placebo/24-h post reperfusion	Metformin 500 mg TID for 3 days before surgery	- <-> 24-h post reperfusion Trop I level and arrhythmia	Short-term metformin pre-surgery did not decrease perioperative myocardial injury or AF in non-DM undergoing cardiac surger		[68]
DM pts undergoing cardiac surgery w/ or w/o metformin (mean age 66 years)	Retrospective matched cohort/metformin 635, non-metformin 648/post-op until hospital discharge	Metformin ≥ 500 mg any time prior to surgery	- <-> post-op AF incidence - post-op AF 26.3% in metformin vs. 30.7% in non-metformin(p = 0.46)	Prior use of metformin in DM patients undergoing cardiac surgery was not associated with decreased post-op AF		[69]

AF atrial fibrillation, AMI acute myocardial infarction, DM diabetes mellitus

Effects of metformin on ventricular arrhythmias: evidence from in vivo studies

Ventricular arrhythmias, which include ventricular tachycardia and ventricular fibrillation (VT/VF), can occur from ischemic and reperfusion (I/R) injury, post-myocardial infarction scar-related reentry, cardiac channelopathy, medication-induced long QT syndrome, or idiopathic [70]. Increased QT interval and QT dispersion reflects prolonged repolarization and inhomogeneity of repolarization, respectively [71]. In diabetes, there are increased corrected QT (QTc) interval and QT dispersion possibly due to alterations in voltage-gated potassium channels [72, 73] and L-type calcium channels [74], and these were associated with a higher risk of sudden cardiac death [75–77]. In animal models, metformin was shown to decrease QT dispersion, and reduce APD and QT interval by inhibiting I_Ca,L [78, 79]. Post-myocardial infarction ventricular arrhythmias occur from reentry around the scarred and slow-conduction myocardial tissues [70]. Administration of metformin for 2 weeks prior to MI induction in mice could reduce cardiac conduction delay (prolonged PR, QT interval, APD, and conduction velocity), rescue inwardly rectifying potassium channel 2.1 (Kir2.1), and increased Cx43 expression by regulating microRNA-1 overexpression [80]. I/R injury performed in animal studies can largely be divided into 2 models, one with partial occlusion of coronary flow or a non-ST elevation myocardial infarction (NSTEMI) I/R model, and another one with total occlusion of coronary flow or ST elevation myocardial infarction (STEMI) I/R model.

In the STEMI I/R rat model, chronic metformin treatment for 3 weeks has been shown to improve cardiac mitochondrial function, intracellular calcium handling, left ventricular pressure rise (LV dP/dt), and heart rate variability [63]. It also reduced markers for oxidative stress (Malondialdehyde- MDA) and infarct size. However, chronic metformin treatment alone was not able to reduce arrhythmia score or mortality rate [63]. Only when chronic metformin treatment was combined with vildagliptin, could the combination increase phosphorylated Connexin43 (pCX43), and consequently delay time to first VT/VF onset, and reduce arrhythmia score, and mortality rate [63]. In addition, there was no difference of plasma glucose level between the control and the treatment groups, suggesting a direct anti-arrhythmic effect of metformin/vildagliptin beyond an anti-hyperglycemia [63]. These findings are consistent with other studies that showed the importance of the role of pCX43 in the pathogenesis of VT/VF in STEMI models [81–85]. Although studies have been performed in STEMI I/R rodent models which showed the beneficial effects of acute metformin administration (18 h to 2 days prior to ischemia), in reducing infarct size and improving LVEF, arrhythmic outcomes were not measured [14, 86, 87].

In a NSTEMI I/R pig model, acute injection of metformin 3 h prior to ischemia did not provide any benefits regarding AMPK activation, LV dP/dt, electrophysiological changes, and most importantly VT/VF incidence [88]. Unlike acute metformin treatment, chronic metformin treatment for 2–3 weeks in a partial coronary artery occlusion model was shown to reduce VT/VF incidence by preventing monophasic action potential shortening and reducing the dispersion of action potential duration between the ischemic/infarct area and normal myocardium via AMPK activation, leading to preservation of myocardial ATP [88]. The anti-VT/VF effect of metformin was not related to a reduction in blood glucose because it was continuously maintained during the experiments at 4.5 ± 0.5 mmol/L with 10% dextrose solution in both control and treatment groups [88].

Evidence from these in vivo reports suggested that chronic treatment with metformin alone might reduce VT/VF incidence in the NSTEMI model, whereas the combination of chronic metformin and vildagliptin was required in order to reduce VT/VF in the STEMI model. In contrast, acute metformin treatment did not have any effect on VT/VF events in the NSTEMI model. However, acute metformin treatment was not tested in the STEMI model. All of these reports are summarized in Table 4. Figure 2 summarized mechanisms behind the protective effects of metformin on ventricular arrhythmias.

Table 4.

Effects of metformin on ventricular arrhythmias: reports from in vivo studies

Model	Metformin (dose/ duration)	Key results and major findings								Interpretation	References
		Energy homeostasis	Oxidative stress	Intra-cellular Ca	LV dP/dt	Infarct/ apoptosis	EP changes	p-Cx 43	VT/ VF
Domestic farm pigs with cardiac I/R injury -I(50% flow)/R = 90/45 min	-Chronic metformin 30 mg/kg/day per oral for 2–3 weeks)	- ↑↑AMPK - ↑CS - ↑ATP - <-> O2, glucose use, lactate	–	–	<->	–	-↓MAP shortening -↓APD dispersion	–	↓	Chronic metformin treatment reduced ischemic VF by preventing MAP shortening and repolarization heterogeneity via AMPK activation, leading to preserved myocardial ATP	[88]
	-Acute Metformin IV 100 mg/kg	<-> AMPK	–	–	<->	–	<->	–	<->
Male Wistar rats fed with high fat for 12 weeks underwent cardiac I/R injury. (LAD ligation 30/R 120 min)	Metformin 30 mg/kg/day for 3 weeks	↑Mito-chondrial function	↓MDA	-↓Diastolic Ca -↑transient amp/decay	↑	↓Infarct/ ↓Bax, ↑Bcl-2	↑HRV	<->	<->	Metformin alone did not reduce VT/VF incidence. However, combined drugs effectively decreased VT/VF via increased p-Cx43	[63]
	Metformin+ Vildagliptin	↑Mito-chondrial function	↓MDA	-↓Diastolic Ca -↑Transient amp/decay	↑	↓Infarct/ ↓Bax, ↑Bcl-2	↑HRV	↑	↓

AMPK 5' adenosine monophosphate-activated protein kinase, APD action potential duration, ATP adenosine triphosphate, Ca calcium, CS citrate synthase, EP electrophysiologic, HRV heart rate variability, I/R ischemic/reperfusion, LAD left anterior descending coronary artery, LV left ventricular, MAP monophasic action potential, MDA malondialdehyde, pAMPK phosphorylated 5' adenosine monophosphate-activated protein kinase, p-Cx phosphorylated Connexin, VT/VF ventricular tachycardia/ventricular fibrillation

Fig. 2.

Effects of metformin on ventricular arrhythmias. Ischemia causes reduction in myocardial ATP and finally results in ventricular fibrillation. Chronic metformin use exerts its energy guardian effects mainly via AMPK activation. Additionally, metformin prevents QT interval prolongation, QT dispersion, and conduction velocity delay by regulating microRNA-1 and L-type calcium channels. Only the combination of metformin and vildagliptin could increase p-Cx43 and subsequently reduce ventricular fibrillation. Green rectangle and arrow shows protective mechanisms of metformin

Effects of metformin on ventricular arrhythmias: evidence from clinical trials

Patients presented with VT/VF who had diabetes portend worse long-term all-cause mortality at 2 years as compared to patients without diabetes [89]. Hyperglycemia was associated with prolonged QT interval, increased QT dispersion, and higher risk of developing VT in acute MI patients [90, 91]. Whether hyperglycemia is the cause of ventricular arrhythmias, or merely a marker of increased sympathetic activity remains uncertain [92]. Although metformin was associated with a decrease in QTc in diabetic patients [93], there was no available data regarding the relationship between achieving acute hyperglycemic control with metformin/anti-diabetic medications and ventricular arrhythmic outcomes.

There were only two clinical trials that directly studied the effects of metformin on ventricular arrhythmias [56, 94]. In a randomized crossover trial, 19 diabetic patients with coronary artery disease (CAD) were randomized to receive either metformin 500 mg twice daily for 2 weeks or placebo. The primary outcomes were number of premature ventricular contractions/non-sustained VT (PVC/NSVT) beats measured by 24-h Holter monitor [94]. Metformin failed to reduce PVC/NSVT in diabetic CAD patients compared to placebo [94]. However, the results should be interpreted with caution due to the small sample size and a lower-than-average dosage (1000 mg per day) [94] as compared to other studies with cardiovascular benefits (1700–2000 mg per day) [8]. Also, this particular study was not performed under ischemic/reperfusion circumstances, which may explain why metformin did not reveal its anti-ventricular arrhythmia benefits as opposed to the positive findings reported in an animal I/R injury model [88]. Therefore, the PVC/NSVT may be associated with mechanisms other than ischemia, such as automaticity or triggered activity, and might not indicate a poor prognosis.

The second study was a retrospective cohort of hospitalized diabetic patients who presented with acute MI [56]. Unfortunately, metformin was not associated with decreased VT/VF incidence within 28-days post MI [56]. Similar to the first report mentioned above, this report has several limitations, including no data regarding type of MI, unreported metformin dosage and duration, and underutilized beta blocker (23%) and thrombolytic reperfusion therapy (21%). All of these reports are summarized in Table 5.

Table 5.

Effects of metformin on ventricular arrhythmias: reports from clinical trials

Model	Type of study/No. of patients/FU	Metformin (dose/duration)	Key results and major findings	Interpretation	References
DM patients with CAD monitored via 24-h Holter monitor (mean age 55)	Randomized crossover design/19 patients/2 weeks	Metformin 500 mg BID for 2 weeks	- <-> PVC/NSVT per minute of ischemia	Metformin did not reduce PVC/NSVT in diabetic CAD patients	[94]
Hospitalized DM patients with AMI (mean age 56)	Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI	Various doses	- <-> 28-days VT/VF incidence	Metformin alone or in combination with other anti-DM drugs was not associated with decreased 28-day post AMI VT/VF incidence	[56]

AMI acute myocardial infarction, CAD coronary artery disease, DM diabetes mellitus, PVC/NSVT premature ventricular contraction/non-sustained ventricular tachycardia, VT/VF ventricular tachycardia/ventricular fibrillation

Ongoing trials and future research

Two ongoing studies are being carried out regarding the effects of metformin on AF. The first study is a phase 4 randomized open-label study aiming to see whether metformin as compared to placebo could reduce AF burden in patients with paroxysmal or persistent AF who have cardiovascular implantable electronic devices (NCT03603912, TRIM-AF study) [95]. The second study was a phase 2 randomized clinical trial which aimed to see whether metformin could help AF patients stay within a normal sinus rhythm after catheter ablation. This second study had an early termination due to unmet enrollment expectations (NCT02931253) [96]. Unfortunately, there is no ongoing clinical trial of the effects of metformin on ventricular arrhythmias (Table 6).

Table 6.

Effect of metformin on arrhythmias: ongoing clinical trials

Model	Status	Type of study/No. of patients/FU	Intervention	Primary outcome	References
Patients with paroxysmal or persistent AF with CIED	Recruiting	Phase 4 Randomized clinical trial/270 patients/2 years	- Metformin 750 mg twice daily × 2 years - Lifestyle/risk factor modification	Change in %AF burden at 1 year	[95]
Patients with AF who underwent AF catheter ablation	Terminated	Phase 2 Randomized clinical trial/6 patients/6 months	- Metformin 1000 mg twice daily	Number of patients who maintain sinus rhythm	[96]

AF atrial fibrillation, CIED cardiovascular implantable electronic device

To progress from the in vivo AF studies, it might be helpful to examine the role of metformin in AF trigger. Since the available reports only assessed AF inducibility and duration after rapid atrial pacing [42, 45], or spontaneous AF detected by surface electrocardiogram [53], this information is not sufficient to determine whether metformin reduced AF by suppressing pulmonary vein triggers or modulating reentry substrate. For in vivo ventricular arrhythmia study, it would be of interest to see whether metformin alone or in combination with a dipeptidyl peptidase-4 inhibitor could reduce ventricular arrhythmias or sudden cardiac death in acute coronary syndrome patients. These hypotheses remain to be elucidated in the future clinical studies.

Although there are some borderline or contradictory results, ample scientific evidence exists to indicate that metformin has potential beneficial effects with regard to atrial and ventricular arrhythmias in human. Adequately-powered randomized controlled trials are needed to clarify the actual effects of metformin both in diabetic and non-diabetic populations. In the case of a study into atrial arrhythmias, use of continuous rhythm monitoring devices, such as an implantable loop recorder, pacemaker, or defibrillator, is strongly encouraged in order to avoid underdetection of AF.

Conclusions

Basic research has demonstrated the protective effects of metformin on both atrial and ventricular arrhythmias via multiple molecular, cellular, electrophysiological, and structural changes. These findings are mostly translated into anti-atrial arrhythmic benefits seen in clinical trials. However, there are exception in some instances, such as in elderly diabetic or post cardiac surgery patients. Currently, there are very limited clinical reports on the effects of metformin on ventricular arrhythmias and the number of ongoing trials is very small. At this point, proper randomized controlled trials are of the utmost importance in order to clarify the beneficial effects of metformin on cardiac arrhythmias.

Abbreviations

AERP

Atrial effective refractory period

AF

Atrial fibrillation

AMPK

5′ adenosine monophosphate-activated protein kinase

APD

Action potential duration

APN

Adiponectin

CAD

Coronary artery disease

Cx43

Connexin-43

DM

Diabetes mellitus

EAT

Epicardial adipose tissue

FPD

Field potential duration

I_Ca,L

L-type calcium current

I/R

Ischemic and reperfusion

K_ATP channel

ATP-sensitive potassium channel

LA

Left atrium

LDL-C

Low-density lipoprotein-cholesterol

LV dP/dt

Left ventricular pressure rise

LVEF

Left ventricular ejection fraction

MAPK

Mitogen-activated protein kinase

MDA

Malondialdehyde

MI

Myocardial infarction

mPTP

Mitochondrial permeability transition pores

NSTEMI

Non-ST elevation myocardial infarction

NSVT

Non-sustained ventricular tachycardia

pCX

Phosphorylated connexin

PI3K/Akt

Phosphatidylinositol-3-kinase/survival protein kinases

PPAR

Peroxisome proliferator-activated receptor

PVC

Premature ventricular contraction

QTc

Corrected QT interval

ROS

Reactive oxygen species

SK current

Small conductance calcium-activated potassium current

STEMI

ST elevation myocardial infarction

TGF-β

Transforming growth factor-beta

TNFα

Tumor necrosis factor alpha

VLCAD

Very long-chain specific acyl-CoA dehydrogenase

VT/VF

Ventricular tachycardia and ventricular fibrillation

ZO-1

Zonula occludens-1

Authors’ contributions

TN, SCC, and NC participated in the conception and the design of the review. TN, WW, SCC, and NC wrote the manuscript. TN and NC revised the whole writing process. All authors read and approved the final manuscript.

Funding

This work was supported by the NSTDA Research Chair grant from the National Science and Technology Development Agency Thailand (NC); the Senior Research Scholar grant from the National Research Council of Thailand (SCC), the Thailand Science Research and Innovation (TSRI) grant (NC), and the Chiang Mai University Center of Excellence Award (NC).

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.